MedTrace Logo

Site Selection for Intracutaneous Saline Delivery

NCT01767324 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-08-02

No results posted yet for this study

Summary

The goal of this exploratory study is to select the optimal body site for intracutaneous delivery of 0.5 milliliters of saline from the FLUGEN 101.2 microneedle-based device.

Conditions

  • Intracutaneous Drug Delivery

Interventions

DEVICE

Injection to deltoid

Deliver 0.5 milliliters of saline intradermally

DEVICE

Injection to forearm

Deliver 0.5 milliliters of saline intradermally

DEVICE

Injection to thigh

Deliver 0.5 milliliters of saline intradermally

Sponsors & Collaborators

  • Accelovance

    collaborator INDUSTRY

  • FluGen Inc

    lead INDUSTRY

Principal Investigators

  • Renee Herber · FluGen Inc

  • Murray A Kimmel, DO · Accelovance

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01767324 on ClinicalTrials.gov